Table 2.
All patients | Node-negative patientsa | Node-positive patientsa | ||||
---|---|---|---|---|---|---|
No. of patients | % | No. of patients | % | No. of patients | % | |
All patients | 653 | 100 | 419 | 64.2 | 218 | 33.4 |
PAM50 intrinsic subtype | ||||||
Luminal A | 341 | 52.2 | 240 | 57.3 | 95 | 43.6 |
Luminal B | 173 | 26.5 | 103 | 24.6 | 65 | 29.8 |
HER2enriched | 69 | 10.6 | 30 | 7.2 | 38 | 17.4 |
Basal-like | 70 | 10.7 | 46 | 11.0 | 20 | 9.2 |
ROR score, median | 51 | 46 | 56 | |||
HR+/HER2− patients | 476 | 100 | 318 | 66.8 | 149 | 31.3 |
ROR risk score classification | ||||||
Low risk | 180 | 37.8 | 145 | 45.6 | 33 | 22.1 |
Intermediate risk | 108 | 22.7 | 104 | 32.7 | – | – |
High risk | 188 | 39.5 | 69 | 21.7 | 116 | 77.9 |
ROR score, median | 46 | 42 | 50 |
Abbreviations: HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, ROR Risk of recurrence
aNine patients were classified as pNX